SCHEMBL3106777

SCHEMBL3106777

CCc1oc(-c2ccc(OC)cc2)cc1C(=O)OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.52
HSD17B10 Q99714 3/20 0.52
KMT2A Q03164 3/20 0.52
MEN1 O00255 2/20 0.52
PKM P14618 2/20 0.52
HTT P42858 1/20 0.52
KDM4E B2RXH2 4/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2D6 P10635 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
EGFR P00533 1/20 0.49
TARBP2 Q15633 1/20 0.47
MAPT P10636 6/20 0.47
HPGD P15428 5/20 0.47
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
TP53 P04637 2/20 0.44
NR4A2 P43354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3102243 0.86 ALDH1A1 (0.52) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3907152 0.85 VDR (0.48) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3105122 0.83 KDM4E (0.47) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3102333 0.81 ALDH1A1 (0.62) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3110166 0.75 EGFR (0.49) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL29859324 0.75 TARBP2 (0.55) ALDH1A1HSD17B10KMT2AMEN1KDM4E
SCHEMBL19934926 0.75 MAOB (0.56) ALDH1A1HSD17B10KMT2AMEN1KDM4E
SCHEMBL3099202 0.74 EGFR (0.51) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3100109 0.74 SLC6A4 (0.47) ALDH1A1HSD17B10KMT2AMEN1PKM
SCHEMBL3106982 0.73 ALDH1A1 (0.51) ALDH1A1HSD17B10KMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2210876-B1 HETEROCYCLIC COMPOUND AS GLUCAGON ANTAGONIST TAKEDA PHARMACEUTICAL (JP) 2015-05-20 EP disclosed
US-8309580-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-13 US disclosed
US-20100256156-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-10-07 US disclosed
EP-2210876-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-07-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256156-A1 HETEROCYCLIC COMPOUND GLP1R, GPR119, GCGR ALDH1A1 3963/4885HSD17B10 1199/4885KMT2A 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.